Evolus (NASDAQ:EOLS) Sets New 1-Year Low – What’s Next?

Evolus, Inc. (NASDAQ:EOLS)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $9.48 and last traded at $9.80, with a volume of 917290 shares changing hands. The stock had previously closed at $10.00.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, November 7th.

Evolus Stock Up 6.3 %

The firm has a 50-day simple moving average of $11.84 and a 200 day simple moving average of $13.72. The stock has a market capitalization of $637.64 million, a P/E ratio of -11.07 and a beta of 1.32. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EOLS. Essex Investment Management Co. LLC increased its position in Evolus by 0.4% in the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after acquiring an additional 1,111 shares during the period. Arizona State Retirement System grew its stake in shares of Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after purchasing an additional 1,253 shares during the last quarter. Creative Planning increased its holdings in Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock valued at $250,000 after purchasing an additional 2,963 shares during the period. Sei Investments Co. raised its position in Evolus by 9.8% during the 2nd quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock worth $367,000 after purchasing an additional 3,020 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in Evolus during the 2nd quarter worth about $43,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.